These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 33962357

  • 1. Pre-clinical evaluation of immunoPET imaging using agonist CD40 monoclonal antibody in pancreatic tumor-bearing mice.
    Aghevlian S, Wu B, Raie MN, Tumbale SK, Kare AJ, Seo JW, Ferrara KW.
    Nucl Med Biol; 2021; 98-99():8-17. PubMed ID: 33962357
    [Abstract] [Full Text] [Related]

  • 2. MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using (64)Cu-NOTA-panitumumab F(ab')2 fragments.
    Boyle AJ, Cao PJ, Hedley DW, Sidhu SS, Winnik MA, Reilly RM.
    Nucl Med Biol; 2015 Feb; 42(2):71-7. PubMed ID: 25456837
    [Abstract] [Full Text] [Related]

  • 3. ImmunoPET Imaging of CD146 in Murine Models of Intrapulmonary Metastasis of Non-Small Cell Lung Cancer.
    England CG, Jiang D, Hernandez R, Sun H, Valdovinos HF, Ehlerding EB, Engle JW, Yang Y, Huang P, Cai W.
    Mol Pharm; 2017 Oct 02; 14(10):3239-3247. PubMed ID: 28825843
    [Abstract] [Full Text] [Related]

  • 4. Radioimmunotherapy of human pancreatic cancer xenografts in NOD-scid mice with [64Cu]Cu-NOTA-panitumumab F(ab')2 alone or combined with radiosensitizing gemcitabine and the PARP inhibitor, rucaparib.
    Boyle AJ, Cao PJ, Cai Z, Chan C, Hedley DW, Reilly RM.
    Nucl Med Biol; 2020 Oct 02; 84-85():46-54. PubMed ID: 32062317
    [Abstract] [Full Text] [Related]

  • 5. Tumor and organ uptake of (64)Cu-labeled MORAb-009 (amatuximab), an anti-mesothelin antibody, by PET imaging and biodistribution studies.
    Lee JH, Kim H, Yao Z, Lee SJ, Szajek LP, Grasso L, Pastan I, Paik CH.
    Nucl Med Biol; 2015 Nov 02; 42(11):880-6. PubMed ID: 26307499
    [Abstract] [Full Text] [Related]

  • 6. Development and preclinical studies of 64Cu-NOTA-pertuzumab F(ab')2 for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CT.
    Lam K, Chan C, Reilly RM.
    MAbs; 2017 Jan 02; 9(1):154-164. PubMed ID: 27813707
    [Abstract] [Full Text] [Related]

  • 7. Imaging cancer using PET--the effect of the bifunctional chelator on the biodistribution of a (64)Cu-labeled antibody.
    Dearling JL, Voss SD, Dunning P, Snay E, Fahey F, Smith SV, Huston JS, Meares CF, Treves ST, Packard AB.
    Nucl Med Biol; 2011 Jan 02; 38(1):29-38. PubMed ID: 21220127
    [Abstract] [Full Text] [Related]

  • 8. Immuno-PET of tissue factor in pancreatic cancer.
    Hong H, Zhang Y, Nayak TR, Engle JW, Wong HC, Liu B, Barnhart TE, Cai W.
    J Nucl Med; 2012 Nov 02; 53(11):1748-54. PubMed ID: 22988057
    [Abstract] [Full Text] [Related]

  • 9. Automated Synthesis and Preclinical Evaluation of Optimized Integrin α6-Targeted Positron Emission Tomography Imaging of Pancreatic Cancer.
    Chen L, Fu H, He H, Lou K, Li Q, Ye J, Feng G, Yu C.
    Mol Pharm; 2023 Aug 07; 20(8):4277-4284. PubMed ID: 37463487
    [Abstract] [Full Text] [Related]

  • 10. 64Cu-Labeled Trastuzumab Fab-PEG24-EGF Radioimmunoconjugates Bispecific for HER2 and EGFR: Pharmacokinetics, Biodistribution, and Tumor Imaging by PET in Comparison to Monospecific Agents.
    Kwon LY, Scollard DA, Reilly RM.
    Mol Pharm; 2017 Feb 06; 14(2):492-501. PubMed ID: 28049295
    [Abstract] [Full Text] [Related]

  • 11. Noninvasive Detection of HER2 Expression in Gastric Cancer by 64Cu-NOTA-Trastuzumab in PDX Mouse Model and in Patients.
    Guo X, Zhu H, Zhou N, Chen Z, Liu T, Liu F, Xu X, Jin H, Shen L, Gao J, Yang Z.
    Mol Pharm; 2018 Nov 05; 15(11):5174-5182. PubMed ID: 30251865
    [Abstract] [Full Text] [Related]

  • 12. A pretargeted PET imaging strategy based on bioorthogonal Diels-Alder click chemistry.
    Zeglis BM, Sevak KK, Reiner T, Mohindra P, Carlin SD, Zanzonico P, Weissleder R, Lewis JS.
    J Nucl Med; 2013 Aug 05; 54(8):1389-96. PubMed ID: 23708196
    [Abstract] [Full Text] [Related]

  • 13. PET Imaging of Tissue Factor in Pancreatic Cancer Using 64Cu-Labeled Active Site-Inhibited Factor VII.
    Nielsen CH, Jeppesen TE, Kristensen LK, Jensen MM, El Ali HH, Madsen J, Wiinberg B, Petersen LC, Kjaer A.
    J Nucl Med; 2016 Jul 05; 57(7):1112-9. PubMed ID: 27013699
    [Abstract] [Full Text] [Related]

  • 14. Comparison of renal clearance of [18F]AlF-RESCA-HER2-BCH and [18F]AlF-NOTA-HER2-BCH in mice and breast cancer patients.
    Liu J, Guo X, Wen L, Wang L, Liu F, Song G, Zhu H, Zhou N, Yang Z.
    Eur J Nucl Med Mol Imaging; 2023 Jul 05; 50(9):2775-2786. PubMed ID: 37093312
    [Abstract] [Full Text] [Related]

  • 15. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.
    Xavier C, Vaneycken I, D'huyvetter M, Heemskerk J, Keyaerts M, Vincke C, Devoogdt N, Muyldermans S, Lahoutte T, Caveliers V.
    J Nucl Med; 2013 May 05; 54(5):776-84. PubMed ID: 23487015
    [Abstract] [Full Text] [Related]

  • 16. Positron emission tomography imaging of CD105 expression with a 64Cu-labeled monoclonal antibody: NOTA is superior to DOTA.
    Zhang Y, Hong H, Engle JW, Bean J, Yang Y, Leigh BR, Barnhart TE, Cai W.
    PLoS One; 2011 May 05; 6(12):e28005. PubMed ID: 22174762
    [Abstract] [Full Text] [Related]

  • 17. Preclinical Evaluation of [64Cu]NOTA-CP01 as a PET Imaging Agent for Metastatic Esophageal Squamous Cell Carcinoma.
    Peng T, Wang X, Li Z, Bi L, Gao J, Yang M, Wang Y, Yao X, Shan H, Jin H.
    Mol Pharm; 2021 Sep 06; 18(9):3638-3648. PubMed ID: 34424706
    [Abstract] [Full Text] [Related]

  • 18. ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer.
    Sun H, England CG, Hernandez R, Graves SA, Majewski RL, Kamkaew A, Jiang D, Barnhart TE, Yang Y, Cai W.
    Eur J Nucl Med Mol Imaging; 2016 Nov 06; 43(12):2169-2179. PubMed ID: 27342417
    [Abstract] [Full Text] [Related]

  • 19. ImmunoPET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer with a Dual-Labeled Bispecific Antibody Fragment.
    Luo H, England CG, Goel S, Graves SA, Ai F, Liu B, Theuer CP, Wong HC, Nickles RJ, Cai W.
    Mol Pharm; 2017 May 01; 14(5):1646-1655. PubMed ID: 28292180
    [Abstract] [Full Text] [Related]

  • 20. Noninvasive Evaluation of CD20 Expression Using 64Cu-Labeled F(ab')2 Fragments of Obinutuzumab in Lymphoma.
    Kang L, Li C, Rosenkrans ZT, Engle JW, Wang R, Jiang D, Xu X, Cai W.
    J Nucl Med; 2021 Mar 01; 62(3):372-378. PubMed ID: 32826320
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.